Abstract
In November 2011, aflibercept (Eylea; Regeneron Pharmaceuticals), a recombinant fusion protein that binds to members of the vascular endothelial growth factor family, was approved by the US Food and Drug Administration (FDA) for the treatment of patients with neovascular age-related macular degeneration.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after aflibercept treatment
BMC Ophthalmology Open Access 22 January 2024
-
Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan
Scientific Reports Open Access 13 January 2022
-
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
International Journal of Retina and Vitreous Open Access 07 December 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Stewart, M. W. The expanding role of vascular endothelial growth factor inhibitors in ophthalmology. Mayo Clin. Proc. 87, 77–88 (2012).
Narayanan, R. et al. Ranibizumab. Nature Rev. Drug Discov. 5, 815–816 (2006).
Holash, J. et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393–11398 (2002).
US Food and Drug Administration. FDA labeling information — Eylea. FDA website [online], (2011).
Martin, D. F. et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897–1908 (2011).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
M.W.S has served on an advisory board and received research support from Regeneron, served on an advisory board for Allergan, and received research support from Bayer.
Rights and permissions
About this article
Cite this article
Stewart, M., Grippon, S. & Kirkpatrick, P. Aflibercept. Nat Rev Drug Discov 11, 269–270 (2012). https://doi.org/10.1038/nrd3700
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3700
This article is cited by
-
Differences in aqueous humor protein profiles in patients with proliferative diabetic retinopathy before and after aflibercept treatment
BMC Ophthalmology (2024)
-
Design, construction and in vivo functional assessment of a hinge truncated sFLT01
Gene Therapy (2023)
-
Diabetic macular edema and proliferative diabetic retinopathy treated with anti-vascular endothelial growth factor under the reimbursement policy in Taiwan
Scientific Reports (2022)
-
Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
International Journal of Retina and Vitreous (2021)
-
Gene expression profile of the murine ischemic retina and its response to Aflibercept (VEGF-Trap)
Scientific Reports (2021)